Hua Medicine (Shanghai) Ltd.

SEHK:2552 Stock Report

Market Cap: HK$1.5b

Hua Medicine (Shanghai) Management

Management criteria checks 3/4

Hua Medicine (Shanghai)'s CEO is Li Chen, appointed in Jun 2010, has a tenure of 14.5 years. total yearly compensation is CN¥17.08M, comprised of 33.6% salary and 66.4% bonuses, including company stock and options. directly owns 3.98% of the company’s shares, worth HK$59.73M. The average tenure of the management team and the board of directors is 4.8 years and 6.3 years respectively.

Key information

Li Chen

Chief executive officer

CN¥17.1m

Total compensation

CEO salary percentage33.6%
CEO tenure14.5yrs
CEO ownership4.0%
Management average tenure4.8yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?

Nov 17
Is Hua Medicine (Shanghai) (HKG:2552) Using Too Much Debt?

Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects

Aug 28
Investors Appear Satisfied With Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Prospects

We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth

Jan 06
We Think Hua Medicine (Shanghai) (HKG:2552) Can Afford To Drive Business Growth

We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow

Aug 02
We're Interested To See How Hua Medicine (Shanghai) (HKG:2552) Uses Its Cash Hoard To Grow

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Apr 22
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Sep 23
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn

Jun 24
We're Not Worried About Hua Medicine (Shanghai)'s (HKG:2552) Cash Burn

Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Mar 22
Companies Like Hua Medicine (Shanghai) (HKG:2552) Can Afford To Invest In Growth

Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook

Feb 21
Hua Medicine (Shanghai) Ltd.'s (HKG:2552) Profit Outlook

Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year

Jan 25
Hua Medicine (Shanghai) (HKG:2552) Shareholders Booked A 21% Gain In The Last Year

Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business

Dec 21
Hua Medicine (Shanghai) (HKG:2552) Is In A Strong Position To Grow Its Business

CEO Compensation Analysis

How has Li Chen's remuneration changed compared to Hua Medicine (Shanghai)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥263m

Mar 31 2024n/an/a

-CN¥237m

Dec 31 2023CN¥17mCN¥6m

-CN¥211m

Sep 30 2023n/an/a

-CN¥200m

Jun 30 2023n/an/a

-CN¥189m

Mar 31 2023n/an/a

-CN¥196m

Dec 31 2022CN¥23mCN¥5m

-CN¥204m

Sep 30 2022n/an/a

-CN¥234m

Jun 30 2022n/an/a

-CN¥265m

Mar 31 2022n/an/a

-CN¥295m

Dec 31 2021CN¥24mCN¥5m

-CN¥326m

Sep 30 2021n/an/a

-CN¥355m

Jun 30 2021n/an/a

-CN¥385m

Mar 31 2021n/an/a

-CN¥389m

Dec 31 2020CN¥28mCN¥5m

-CN¥393m

Sep 30 2020n/an/a

-CN¥378m

Jun 30 2020n/an/a

-CN¥363m

Mar 31 2020n/an/a

-CN¥394m

Dec 31 2019CN¥28mCN¥4m

-CN¥425m

Sep 30 2019n/an/a

-CN¥1b

Jun 30 2019n/an/a

-CN¥2b

Mar 31 2019n/an/a

-CN¥3b

Dec 31 2018CN¥12mCN¥2m

-CN¥4b

Sep 30 2018n/an/a

-CN¥3b

Jun 30 2018n/an/a

-CN¥2b

Mar 31 2018n/an/a

-CN¥440m

Dec 31 2017CN¥4mCN¥3m

-CN¥273m

Compensation vs Market: Li's total compensation ($USD2.34M) is above average for companies of similar size in the Hong Kong market ($USD346.63K).

Compensation vs Earnings: Li's compensation has been consistent with company performance over the past year.

CEO

Li Chen (61 yo)

14.5yrs

Tenure

CN¥17,083,000

Compensation

Dr. Li Chen, Ph.D. is the Co-Founder of Hua Medicine (Shanghai) Ltd. and served as its Chief Scientific Officer until 2022 and served as its President until May 19, 2016 and has been its Chief Executive Of...

Leadership Team

NamePositionTenureCompensationOwnership
Li Chen
Founder14.5yrsCN¥17.08m3.98%
HK$ 59.7m
Chien Cheng Lin
Executive VP & Chief Strategy Officer1.8yrsCN¥7.16m0.87%
HK$ 13.0m
Fuxing Tang
CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA4.8yrsno datano data
Changhong Li
Chief Scientific Officer2yrsno datano data
Chengde Wang
Head of IRno datano datano data
Yi Zhang
Senior VP of Pharma Development6.7yrsno datano data
Ying Xie
VP of Quality Assurance Division & Chief Quality Officer1.6yrsno datano data
Wing Yan Yuen
Company Secretary5yrsno datano data

4.8yrs

Average Tenure

55yo

Average Age

Experienced Management: 2552's management team is considered experienced (4.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Li Chen
Founder14.5yrsCN¥17.08m3.98%
HK$ 59.7m
Yi Zhang
Senior VP of Pharma Developmentless than a yearno datano data
Robert Taylor Nelsen
Non-Executive Chairman14.7yrsno data0.015%
HK$ 229.5k
Bennett Shapiro
Member of Scientific Advisory Boardno datano datano data
Yiu Wa Tsui
Independent Non-Executive Director6.3yrsCN¥450.00k0.0024%
HK$ 36.8k
Catherine D. Strader
Member of Scientific Advisory Boardno datano datano data
William Robert Keller
Independent Non-Executive Director6.3yrsCN¥540.00kno data
James MacDonald
Member of Scientific Advisory Boardno datano datano data
Yiu Leung Cheung
Independent Non-Executive Director1.9yrsCN¥540.00kno data
Fangxin Li
Non-Executive Director1.2yrsno datano data

6.3yrs

Average Tenure

64yo

Average Age

Experienced Board: 2552's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 11:40
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hua Medicine (Shanghai) Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCLSA
Bo LiCLSA
Ziyi ChenGoldman Sachs